Stuart Larson, MD
Psychiatry · Danville, KYNPI 1124178009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,757, more than ten times the $24 reported in 2019. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$864
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$820
- Otsuka America Pharmaceutical, Inc.$611
- Alkermes, Inc.$588
- Vanda Pharmaceuticals Inc.$500
- Axsome Therapeutics, Inc.$491
- plus $3K from 15 others
What the payments were for
- Food & beverage$6,83999%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $864 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $820 |
| Otsuka America Pharmaceutical, Inc. | 39 | $611 |
| Alkermes, Inc. | 34 | $588 |
| Vanda Pharmaceuticals Inc. | 32 | $500 |
| Axsome Therapeutics, Inc. | 24 | $491 |
| Johnson & Johnson | 21 | $488 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $391 |
| Supernus Pharmaceuticals, Inc. | 13 | $376 |
| Corium, LLC | 20 | $374 |
| E.r. Squibb & Sons, L.L.C. | 16 | $348 |
| Almatica Pharma LLC | 11 | $250 |
| Neurocrine Biosciences, Inc. | 12 | $204 |
| Teva Pharmaceuticals USA, Inc. | 9 | $173 |
| Lundbeck LLC | 6 | $125 |
| Sunovion Pharmaceuticals Inc. | 4 | $78 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Biogen | 3 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $24 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$193
How this compares
$6,888 in reported general payments places this provider in the 90th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $150,945 |
| Invega SustennaPaliperidone Palmitate | 25 | $92,613 |
| RexultiBrexpiprazole | 49 | $76,133 |
| CaplytaLumateperone Tosylate | 26 | $66,686 |
| VraylarCariprazine Hcl | 36 | $56,035 |
| AuvelityDextromethorphan Hbr/Bupropion | 32 | $41,826 |
| TrintellixVortioxetine Hydrobromide | 55 | $38,524 |
| Aripiprazole | 164 | $17,775 |
| Lurasidone Hcl | 88 | $16,041 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $14,670 |
| Lisdexamfetamine Dimesylate | 75 | $13,692 |
| Paliperidone ErPaliperidone | 19 | $10,120 |
| Bupropion XlBupropion Hcl | 392 | $5,851 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 59 | $5,206 |
| Clonazepam | 639 | $5,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $204 | $150,94518 claims |
| Johnson & JohnsonInvega Sustenna | $488 | $92,61325 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $611 | $76,13349 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $820 | $66,68626 claims |
| AbbVieVraylar | $864 | $56,03536 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $391 | $53,19493 claims |
| Axsome Therapeutics, Inc.Auvelity | $491 | $41,82632 claims |
| Almatica Pharma LLCSertraline Hcl | $250 | $1,346176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Danville
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Steven CroleyLexington$151K
- Joseph HarrisonOwensboro$131K
- Stephanie HallLouisville$106K
- Jacob BishopLexington$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.